Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo

A mathematical modeling approach

R. Rockne, J. K. Rockhill, Maciej Mrugala, A. M. Spence, I. Kalet, K. Hendrickson, A. Lai, T. Cloughesy, E. C. Alvord, Kristin Swanson

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) is the most malignant form of primary brain tumors known as gliomas. They proliferate and invade extensively and yield short life expectancies despite aggressive treatment. Response to treatment is usually measured in terms of the survival of groups of patients treated similarly, but this statistical approach misses the subgroups that may have responded to or may have been injured by treatment. Such statistics offer scant reassurance to individual patients who have suffered through these treatments. Furthermore, current imaging-based treatment response metrics in individual patients ignore patient-specific differences in tumor growth kinetics, which have been shown to vary widely across patients even within the same histological diagnosis and, unfortunately, these metrics have shown only minimal success in predicting patient outcome. We consider nine newly diagnosed GBM patients receiving diagnostic biopsy followed by standard-of-care external beam radiation therapy (XRT). We present and apply a patient-specific, biologically based mathematical model for glioma growth that quantifies response to XRT in individual patients in vivo. The mathematical model uses net rates of proliferation and migration of malignant tumor cells to characterize the tumor's growth and invasion along with the linear-quadratic model for the response to radiation therapy. Using only routinely available pre-treatment MRIs to inform the patient-specific bio-mathematical model simulations, we find that radiation response in these patients, quantified by both clinical and model-generated measures, could have been predicted prior to treatment with high accuracy. Specifically, we find that the net proliferation rate is correlated with the radiation response parameter (r = 0.89, p = 0.0007), resulting in a predictive relationship that is tested with a leave-one-out cross-validation technique. This relationship predicts the tumor size post-therapy to within inter-observer tumor volume uncertainty. The results of this study suggest that a mathematical model can create a virtual in silico tumor with the same growth kinetics as a particular patient and can not only predict treatment response in individual patients in vivo but also provide a basis for evaluation of response in each patient to any given therapy.

Original languageEnglish (US)
Pages (from-to)3271-3285
Number of pages15
JournalPhysics in Medicine and Biology
Volume55
Issue number12
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Glioblastoma
Radiotherapy
Theoretical Models
Therapeutics
Neoplasms
Growth
Glioma
Radiation
Standard of Care
Life Expectancy
Tumor Burden
Brain Neoplasms
Computer Simulation
Uncertainty
Linear Models

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo : A mathematical modeling approach. / Rockne, R.; Rockhill, J. K.; Mrugala, Maciej; Spence, A. M.; Kalet, I.; Hendrickson, K.; Lai, A.; Cloughesy, T.; Alvord, E. C.; Swanson, Kristin.

In: Physics in Medicine and Biology, Vol. 55, No. 12, 2010, p. 3271-3285.

Research output: Contribution to journalArticle

Rockne, R. ; Rockhill, J. K. ; Mrugala, Maciej ; Spence, A. M. ; Kalet, I. ; Hendrickson, K. ; Lai, A. ; Cloughesy, T. ; Alvord, E. C. ; Swanson, Kristin. / Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo : A mathematical modeling approach. In: Physics in Medicine and Biology. 2010 ; Vol. 55, No. 12. pp. 3271-3285.
@article{30ab0731798742c39a1e8d6bad18a97a,
title = "Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: A mathematical modeling approach",
abstract = "Glioblastoma multiforme (GBM) is the most malignant form of primary brain tumors known as gliomas. They proliferate and invade extensively and yield short life expectancies despite aggressive treatment. Response to treatment is usually measured in terms of the survival of groups of patients treated similarly, but this statistical approach misses the subgroups that may have responded to or may have been injured by treatment. Such statistics offer scant reassurance to individual patients who have suffered through these treatments. Furthermore, current imaging-based treatment response metrics in individual patients ignore patient-specific differences in tumor growth kinetics, which have been shown to vary widely across patients even within the same histological diagnosis and, unfortunately, these metrics have shown only minimal success in predicting patient outcome. We consider nine newly diagnosed GBM patients receiving diagnostic biopsy followed by standard-of-care external beam radiation therapy (XRT). We present and apply a patient-specific, biologically based mathematical model for glioma growth that quantifies response to XRT in individual patients in vivo. The mathematical model uses net rates of proliferation and migration of malignant tumor cells to characterize the tumor's growth and invasion along with the linear-quadratic model for the response to radiation therapy. Using only routinely available pre-treatment MRIs to inform the patient-specific bio-mathematical model simulations, we find that radiation response in these patients, quantified by both clinical and model-generated measures, could have been predicted prior to treatment with high accuracy. Specifically, we find that the net proliferation rate is correlated with the radiation response parameter (r = 0.89, p = 0.0007), resulting in a predictive relationship that is tested with a leave-one-out cross-validation technique. This relationship predicts the tumor size post-therapy to within inter-observer tumor volume uncertainty. The results of this study suggest that a mathematical model can create a virtual in silico tumor with the same growth kinetics as a particular patient and can not only predict treatment response in individual patients in vivo but also provide a basis for evaluation of response in each patient to any given therapy.",
author = "R. Rockne and Rockhill, {J. K.} and Maciej Mrugala and Spence, {A. M.} and I. Kalet and K. Hendrickson and A. Lai and T. Cloughesy and Alvord, {E. C.} and Kristin Swanson",
year = "2010",
doi = "10.1088/0031-9155/55/12/001",
language = "English (US)",
volume = "55",
pages = "3271--3285",
journal = "Physics in Medicine and Biology",
issn = "0031-9155",
publisher = "IOP Publishing Ltd.",
number = "12",

}

TY - JOUR

T1 - Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo

T2 - A mathematical modeling approach

AU - Rockne, R.

AU - Rockhill, J. K.

AU - Mrugala, Maciej

AU - Spence, A. M.

AU - Kalet, I.

AU - Hendrickson, K.

AU - Lai, A.

AU - Cloughesy, T.

AU - Alvord, E. C.

AU - Swanson, Kristin

PY - 2010

Y1 - 2010

N2 - Glioblastoma multiforme (GBM) is the most malignant form of primary brain tumors known as gliomas. They proliferate and invade extensively and yield short life expectancies despite aggressive treatment. Response to treatment is usually measured in terms of the survival of groups of patients treated similarly, but this statistical approach misses the subgroups that may have responded to or may have been injured by treatment. Such statistics offer scant reassurance to individual patients who have suffered through these treatments. Furthermore, current imaging-based treatment response metrics in individual patients ignore patient-specific differences in tumor growth kinetics, which have been shown to vary widely across patients even within the same histological diagnosis and, unfortunately, these metrics have shown only minimal success in predicting patient outcome. We consider nine newly diagnosed GBM patients receiving diagnostic biopsy followed by standard-of-care external beam radiation therapy (XRT). We present and apply a patient-specific, biologically based mathematical model for glioma growth that quantifies response to XRT in individual patients in vivo. The mathematical model uses net rates of proliferation and migration of malignant tumor cells to characterize the tumor's growth and invasion along with the linear-quadratic model for the response to radiation therapy. Using only routinely available pre-treatment MRIs to inform the patient-specific bio-mathematical model simulations, we find that radiation response in these patients, quantified by both clinical and model-generated measures, could have been predicted prior to treatment with high accuracy. Specifically, we find that the net proliferation rate is correlated with the radiation response parameter (r = 0.89, p = 0.0007), resulting in a predictive relationship that is tested with a leave-one-out cross-validation technique. This relationship predicts the tumor size post-therapy to within inter-observer tumor volume uncertainty. The results of this study suggest that a mathematical model can create a virtual in silico tumor with the same growth kinetics as a particular patient and can not only predict treatment response in individual patients in vivo but also provide a basis for evaluation of response in each patient to any given therapy.

AB - Glioblastoma multiforme (GBM) is the most malignant form of primary brain tumors known as gliomas. They proliferate and invade extensively and yield short life expectancies despite aggressive treatment. Response to treatment is usually measured in terms of the survival of groups of patients treated similarly, but this statistical approach misses the subgroups that may have responded to or may have been injured by treatment. Such statistics offer scant reassurance to individual patients who have suffered through these treatments. Furthermore, current imaging-based treatment response metrics in individual patients ignore patient-specific differences in tumor growth kinetics, which have been shown to vary widely across patients even within the same histological diagnosis and, unfortunately, these metrics have shown only minimal success in predicting patient outcome. We consider nine newly diagnosed GBM patients receiving diagnostic biopsy followed by standard-of-care external beam radiation therapy (XRT). We present and apply a patient-specific, biologically based mathematical model for glioma growth that quantifies response to XRT in individual patients in vivo. The mathematical model uses net rates of proliferation and migration of malignant tumor cells to characterize the tumor's growth and invasion along with the linear-quadratic model for the response to radiation therapy. Using only routinely available pre-treatment MRIs to inform the patient-specific bio-mathematical model simulations, we find that radiation response in these patients, quantified by both clinical and model-generated measures, could have been predicted prior to treatment with high accuracy. Specifically, we find that the net proliferation rate is correlated with the radiation response parameter (r = 0.89, p = 0.0007), resulting in a predictive relationship that is tested with a leave-one-out cross-validation technique. This relationship predicts the tumor size post-therapy to within inter-observer tumor volume uncertainty. The results of this study suggest that a mathematical model can create a virtual in silico tumor with the same growth kinetics as a particular patient and can not only predict treatment response in individual patients in vivo but also provide a basis for evaluation of response in each patient to any given therapy.

UR - http://www.scopus.com/inward/record.url?scp=77952622122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952622122&partnerID=8YFLogxK

U2 - 10.1088/0031-9155/55/12/001

DO - 10.1088/0031-9155/55/12/001

M3 - Article

VL - 55

SP - 3271

EP - 3285

JO - Physics in Medicine and Biology

JF - Physics in Medicine and Biology

SN - 0031-9155

IS - 12

ER -